These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26501147)

  • 1. Comparative Effect of a Renin Inhibitor and a Thiazide Diuretic on Renal Tissue Oxygenation in Hypertensive Patients.
    Vakilzadeh N; Muller ME; Forni V; Milani B; Hoffman L; Piskunowicz M; Maillard M; Zweiacker C; Pruijm M; Burnier M
    Kidney Blood Press Res; 2015; 40(5):542-54. PubMed ID: 26501147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
    Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
    Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
    J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
    Geiger H; Barranco E; Gorostidi M; Taylor A; Zhang X; Xiang Z; Zhang J
    J Clin Hypertens (Greenwich); 2009 Jun; 11(6):324-32. PubMed ID: 19527323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
    Liu Y; Yan R; Song A; Niu X; Cao C; Wei J; Dong X; Gao D
    Am J Hypertens; 2014 Feb; 27(2):268-78. PubMed ID: 24304656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients.
    Okada Y; Shibata S; Fujimoto N; Best SA; Levine BD; Fu Q
    Am J Physiol Regul Integr Comp Physiol; 2017 Oct; 313(4):R400-R409. PubMed ID: 28724547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.
    Baldwin CM; Plosker GL
    Drugs; 2009; 69(7):833-41. PubMed ID: 19441870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
    J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.
    Sureshkumar KK
    Vasc Health Risk Manag; 2008; 4(6):1205-20. PubMed ID: 19337534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study.
    Basile J; Babazadeh S; Lillestol M; Botha J; Yurkovic C; Weitzman R
    J Clin Hypertens (Greenwich); 2011 Mar; 13(3):162-9. PubMed ID: 21366847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
    Ferdinand KC; Pool J; Weitzman R; Purkayastha D; Townsend R
    J Clin Hypertens (Greenwich); 2011 May; 13(5):366-75. PubMed ID: 21545398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
    Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
    J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
    Makówka A; Olejniczak-Fortak M; Nowicki M
    Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
    Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
    Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.